Search

everythinglearnresearchcommunity

for

Search:↓

Gene variant linked to prostate cancer, hormone levels, and hair loss.

Eating more omega-3 and less omega-6 fatty acids may lower the risk of developing prostate cancer.

5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.

Men with male pattern baldness have a higher risk of aggressive prostate cancer and benign prostatic hyperplasia.

Selenium and vitamin E supplements have mixed effects on prostate cancer risk and may not be beneficial for everyone.

Men with vertex baldness may have a higher risk of developing prostate cancer, but more research is needed to confirm this.

Male pattern baldness may predict prostate cancer risk.

Men who experienced baldness at age 20 may have double the risk of getting prostate cancer.

Early-onset baldness is linked to a higher risk of aggressive prostate cancer in African-American men, especially before age 60.

Finasteride reduces prostate cancer risk but may increase high-grade cancer chances.

The length of the CAG repeat in the androgen receptor gene affects the risk and progression of prostate cancer, BPH, infertility, and undermasculinized genitalia.

Serum triglyceride levels are not linked to prostate cancer risk.

5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.

Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.

Testosterone replacement therapy improved blood sugar and fat levels without raising prostate cancer risk in Japanese men with low testosterone.

The document suggests that blocking sweat glands with antiperspirants might allow skin-generated hormones to be absorbed, possibly increasing breast and prostate cancer risk.

Suppressing certain hormones might help prevent prostate cancer.

Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.

The document does not confirm if radical prostatectomy is the best treatment for locally advanced prostate cancer.

Men with male pattern baldness have a higher risk of certain skin cancers, especially on the scalp.

ERG increases SOX9, promoting prostate cancer growth and invasion.

PSA testing is a reliable method for detecting prostate cancer, and opioids may lower PSA levels, but triglycerides don't affect prostate cancer risk.

Higher urethral PSA levels after prostate removal surgery may be linked to more hair loss and higher PSA levels post-surgery.

The study found no link between baldness patterns and androgen levels in men with benign prostate enlargement or prostate cancer.

Low testosterone does not prevent prostate cancer in men with type 1 diabetes.

Dehydroepiandrosterone (DHEA) is a prohormone important for producing sex steroids and has potential health benefits.

Testing for CAG repeat polymorphism in the androgen receptor gene is not currently recommended for managing hypogonadism.

New compounds show promise for treating hair loss, enlarged prostate, and prostate cancer, with some being more effective and having different side effects than current treatments.

Dutasteride effectively treats enlarged prostate, reduces prostate cancer risk, and promotes hair regrowth with few side effects.

Higher testosterone and DHT levels are linked to hair loss in men, but not to prostate cancer risk.